Incidence,prevalence,and economic burden of sarcoidosis in Puerto Rico: Estimates from a government health insurance claims database

Abstract

Objectives

To estimate the epidemiology of sarcoidosis in Puerto Rico.

Methods

Patients with a diagnosis of sarcoidosis between January 2015 and December 2018 were selected from the Puerto Rico Health Insurance Administration Administración de Seguros de Salud de Puerto Rico claims database. The International Classification of Diseases-Tenth Revision coding for sarcoidosis was used for case detection and utilization of health care services. Cases by sex and age were evaluated.

Results

A total of 488 individuals with sarcoidosis were identified over the 4-year study. The median age at diagnosis was 59 years old. The average annual incidence rate was 9.9/100,000. The baseline prevalence was 14.9 per 100,000. Females represented 68.4% of the cases. Patients with lung and unspecified sarcoidosis predominate with 45.6% and 28.2% of cases, respectively. Overall, the yearly cost of health care utilization and medications per patient was $234 and $13,638, respectively.

Conclusions

Annual incidence rate and the median age of sarcoidosis in Puerto Ricans are among the highest and oldest reported globally. The demographic profile of sarcoidosis in Puerto Rico presents a patient in the mid-to advanced age, mostly female. While costs for medications were relatively high for a patient with sarcoidosis, the economic burden of the disease to the national health care system is not substantial.

Keywords

Epidemiology chronic disorder sarcoidosis health care insurance database Puerto Rico

Get full access to this article

View all access options for this article.

References

WebMD LLC. New York: Sarcoidosis; c2019. https://emedicine.medscape.com/article/301914-overview#a1 (accessed 27 June 2019)

Llanos

Hamzeh

. Sarcoidosis. Med Clin N Am 2019; 103: 527–534. Doi: 10.1016/j.mcna.2018.12.011

Arkema

Cozier

. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis 2018; 9: 227–240. Doi: 10.1177/2040622318790197

Baughman

Field

Costabel

, et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc 2016; 13: 1244–1252. PMID: 27509154. Doi: 10.1513/AnnalsATS.201511-760OC

Cleveland Clinic. Ohio: Sarcoidosis overview; c2015. https://my.clevelandclinic.org/health/diseases/11863 (accessed 19 June 2019).

Aladesanmi

. Sarcoidosis: an update for the primary care physician. MedGenMed 2004; 6: 7. PMID: 15208520; PMCID: PMC1140732.

Thomeer

Demedts

Wuyts

. Epidemiology of sarcoidosis. In: Drent M, Costable U, editors. Sarcoidosis. Eur Respir Soc J LTD UK. 2005; 32: 13–22.

Gerke

Judson

Cozier

, et al. Disease burden and variability in sarcoidosis. Ann Am Thorac Soc 2017; 14: S421–S428. PMID: 29087725; PMCID: PMC5802572. Doi: 10.1513/AnnalsATS.201707-564OT

Centers for Medicare & Medicaid Services. Maryland. Puerto Rico: Medicaid overview. C2019 [19 June 2019]. https://www.medicaid.gov/state-overviews/puerto-rico.html (accessed 19 June 2019).

10.

Health in the Americas – Puerto Rico. Pan American Health Organization, WHO. https://www.paho.org/en (2017, accessed 8 February 2021).

11.

Administración de Seguros de Salud de Puerto Rico [Internet] Puerto Rico. C2019. https://www.asespr.org/i/ (accessed 5 February 2019).

12.

Sundararajan

Henderson

Perry

, et al. New ICD-10 version of the charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004; 57: 1288–1294 PMID: 15617955. Doi: 10.1016/j.jclinepi.2004.03.012

13.

Warnes

Balker

Lumley

, et al. G models: various R programming tools for model fitting: r package version 2.18.1. 2018. https://CRAN-R-project.org/package=gmodels

14.

Alex

. CompareDF: do a git style diff of the rows between two dataframes with similar structure. Version1.8.0 [software]. 2019. https://CRAN.R-project.org/package=compareDF (accessed 20 September 2019)

15.

Aragon

. Epitools: epidemiology tools. R package version 0.5-101. 2020. https://CRAN.R-project.org/package=epitools

16.

Dunn

Smith

. Generalized linear models: estimation. In Dunn

(ed.) Generalized linear models with examples in R. New York: Springer, 2018, pp. 243–263.

17.

Agresti

. Introduction to generalized linear models. Chapter 4 In: Balding

Cressie

NAC

Fitzmaurice

, et al. (eds) Categorical data analysis. USA: John Wiley & Sons, 2013, pp. 113–162.

18.

Wickham

. Ggplot2: elegant graphics for data analysis. 2nd ed. New York: Springer-Verlag New York, 2016.

19.

Coquart

Cadelis

Tressières

, et al. Epidemiology of sarcoidosis in afro- Caribbean people: a 7-year retrospective study in Guadeloupe. Int J Dermatol 2015; 54: 188–192. Epub 25 June 2014. PMID: 24962008. Doi: 10.1111/ijd.12633

20.

Duchemann

Annesi-Maesano

Jacobe de Naurois

, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of greater Paris. Eur Respir J 2017; 50: 1602419. PMID: 28775045. Doi: 10.1183/13993003.02419-2016.

21.

Morimoto

Azuma

Abe

, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008; 31: 372–379. Epub 24 October 2007. PMID: 17959635. Doi: 10.1183/09031936.00075307.

22.

Park

Kim

Kang

, et al. Prevalence, incidence, and mortality of sarcoidosis in Korea, 2003–2015: a nationwide population-based study. Respir Med 2018; 144S: S28–S34. Epub 3 April 2018. PMID: 29631888. Doi: 10.1016/j.rmed.2018.03.028.

23.

Arkema

Grunewald

Kullberg

, et al. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J 2016; 48: 1690–1699. 28 July 2016. PMID: 27471207. Doi: 10:1183/13993003.00477-2016.

24.

Rybicki

Maliarik

Major

, et al. Epidemiology, demographics, and genetics of sarcoidosis. Semin Respir Infect 1998; 13: 166–173. PMID: 9764947.

25.

Dumas

Abramovitz

Wiley

, et al. Epidemiology of sarcoidosis in a prospective cohort study of U.S. Women. Ann Am Thorac Soc 2016; 13: 67–71. PMID: 26501211; PMCID: PMC4722845.

26.

Statement on sarcoidosis. Joint statement of the American thoracic society (ATS), the european respiratory society (ERS) and the world association of sarcoidosis and other granulomatous disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736–755. PMID: 10430755. Doi: 10.1164/ajrccm.160.2.ats4-99.

27.

Rodrigues

Coletta

Ferreira

, et al. Delayed diagnosis of sarcoidosis is common in Brazil. J Bras Pneumol 2013; 39: 539–546. PMID: 24310626; PMCID: PMC4075888. Doi: 10.1590/S1806-37132013000500003.

28.

Perreira

Peters

Lallemand

, et al. Puerto Rico Health Care Infrastructure Assessment, Site Visit Report. Urban Institute, 2017. https://www.urban.org/sites/default/files/publication/87011/2001050-puerto-rico-health-care-infratructure-assessment-site-visit-report_1.pdf (accessed 7 July 2021)

29.

Baughman

Teirstein

Judson

, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885–1889. PMID: 11734441. Doi: 10.1164/ajrccm.164.10.2104046.

30.

Martusewicz-Boros

Boros

Wiatr

, et al. What comorbidities accompany sarcoidosis? A large cohort (n = 1779) patients analysis. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: 115–120. PMID: 26278690.

31.

Soto-Gomez

Peters

Nambiar

. Diagnosis and management of sarcoidosis. Am Fam Physician 2016; 93: 840–848. PMID: 27175719.

32.

Carrillo-Pérez

Apodaca-Cháveza

Carrillo-Maravilla

, et al. Sarcoidosis: a single hospital-based study in a 24-year period. Rev Invest Clin 2015; 67: 33–38. PMID: 25857582.

33.

Foundation for Sarcoidosis Research [Internet]. Chicago: Sarcoidosis treatment guidelines; c2017. https://www.stopsarcoidosis.org/what-is-sarcoidosis/sarcoidosis-treatment-guide/ (accessed 7 June 2020).

34.

Gerke

. Treatment of sarcoidosis: a multidisciplinary approach. Front Immunol 2020; 11: 545413. PMID: 33329511; PMCID: PMC7732561. Doi: 10.3389/fimmu.2020.545413.

35.

Rice

White

Lopez

, et al. High-Cost sarcoidosis patients in the United States: patient characteristics and patterns of health care resource utilization. J Manag Care Spec Pharm 2017; 23: 1261–1269. Epub 17 October 2017. PMID: 29172980.

36.

Hammen

Sherson

Davidsen

. Systemic sarcoidosis mimicking malignant metastatic disease. Eur Clin Respir J 2015; 2: 26761. PMID: 26672956; PMCID: PMC4653310. Doi: 10.3402/ecrj.v2.26761.